🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
46.53
+0.12 (0.26%)
Nov 20, 2026, 4:00 PM EST - Market closed

Company Description

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.

Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.

The company was founded in 2019 and is based in Burlingame, California.

Enliven Therapeutics, Inc.
Enliven Therapeutics logo
CountryUnited States
Founded2016
IPO DateMar 12, 2020
IndustryBiotechnology
SectorHealthcare
Employees65
CEORichard Fair

Contact Details

Address:
205 Park Road
Burlingame, California 94010
United States
Phone(650) 547-5814
Websiteenliventherapeutics.com

Stock Details

Ticker SymbolELVN
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$16.00
CIK Code1672619
CUSIP Number29337E102
ISIN NumberUS29337E1029
Employer ID81-1523849
SIC Code2834

Key Executives

NamePosition
Richard A. Fair M.B.A.Chief Executive Officer, President and Director
Samuel S. Kintz M.B.A.Co-Founder and Head of Pipeline
Benjamin HohlChief Financial Officer and Head of Corporate Development
Dr. Helen Louise Collins M.D.Chief Medical Officer
Dr. Joseph P. Lyssikatos Ph.D.Co-Founder and Research Fellow
Anish Patel Pharm.D.Co-Founder and Chief Operating Officer
Dr. Galya D. Blachman Esq., Ph.D.Chief Legal Officer and Head of Business Development
Damiette SmitVice President of Clinical Development

Latest SEC Filings

DateTypeTitle
Nov 16, 2026SCHEDULE 13G/AFiling
Nov 5, 202610-QQuarterly Report
Nov 5, 20268-KCurrent Report
Oct 27, 2026SCHEDULE 13G/AFiling
Oct 19, 2026144Filing
Oct 14, 20268-KCurrent Report
Oct 1, 2026144Filing
Sep 17, 2026144Filing
Sep 4, 2026144Filing
Aug 6, 2026SCHEDULE 13G/AFiling
Investor Relations Documents
Annual and quarterly reports, earnings releases, and presentation slides